[H-3]nisoxetine - A radioligand for noradrenaline reuptake sites: Correlation with inhibition of [H-3]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments

Nisoxetine is a potent and selective inhibitor of noradrenaline uptake into noradrenergic neurones. [H-3]Nisoxetine binding to rat frontal cortical membranes was of high affinity. The binding data of both competition and saturation studies fitted a single site binding model. [H-3]Nisoxetine binding was potently inhibited by the selective noradrenaline uptake inhibitors desipramine and protriptyline. In addition, a very good correlation was obtained between the ability of 25 monoamine reuptake inhibitors and related compounds both to inhibit [H-3]nisoxetine binding and to inhibit [H-3]noradrenaline uptake in rat frontal cortex. DSP-4 (10-100 mg/kg, i.p.) dose-dependently depleted cortical noradrenaline concentrations (51-100%), with no significant effects on 5-HT and dopamine. These depletions, which were used as a marker of loss of noradrenergic nerve terminals, were associated with a dose-dependent decrease in the number of [H-3]nisoxetine binding sites (20-97%) with no change in binding affinity. Furthermore; a good correlation was obtained between cortical noradrenaline concentrations and the number of [H-3]nisoxetine binding sites. These data support the view that [H-3]nisoxetine binds to a single population of homogeneous sites associated with the noradrenaline transporter complex. Using this ligand, the effects of repeated administration of both antidepressant drugs with a range of pharmacological actions and of electroconvulsive shock on noradrenaline reuptake sites were examined. The number and affinity of [H-3]nisoxetine binding sites were unaltered by all treatments. It is unlikely, therefore, that antidepressant therapy would produce adaptive changes in noradrenaline uptake sites.